Table 1 Table showing the characteristics of the humansamples analysed in the present study. The total number (N) ofsamples and the median age with its interquartile range areshown for every group: Young and aged controls (Con),asymptomatic ALS patients (Asympt.), patients carrying a knowngenetic mutation (gALS) and patients without any identifiedgenetic mutation (sALS)
From: Reduction of ephrin-A5 aggravates disease progression in amyotrophic lateral sclerosis
| Â | Con (young) | Con (aged) | Asympt. ALS | gALS | sALS |
|---|---|---|---|---|---|
N (f/m) | 24 (14/10) | 32 (13/19) | 21 (14/7) | 38 (14/24) | 70 (25/45) |
Age (yr) | 42 (31-50) | 63 (57-72) | 45 (35-51) | 59 (51-67) | 65 (56-70) |